Immediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSM
Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.
Open conversations between care providers and Black women are vitally important in order to empower women with information about HIV and how to protect their health.
Sept. 10, 2020: Concomitant use of vaginal rings with condoms; benefits of more frequent HIV screening for young MSM; Black MSM, substance use, and the PrEP continuum; HIV outcomes stratified by anti-LGTBQ policy across U.S. states.
Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.
Already dealing with legal pushbacks, harm-reduction advocates for safe drug consumption sites now have COVID-19 to blame for slow progress.
Washington, D.C. area community organizations and clinics have moved a lot of prevention efforts online, but much is missing without in-person contact.
Aug. 20, 2020: HIV knowledge and stigma among health care workers in the southern U.S.; condomless sex vs. HIV risk among MSM; how drug class choice may affect onward transmission risk; STI screening rates among MSM on PrEP.
With Several Curative Therapies for Hepatitis C on the Market, the Research Pipeline for Prevention Continues
The authors of an influential annual report on hepatitis C research and development talk through what's new and evolving in clinical science.
A Vaginal Ring to Prevent HIV Was Given a Positive Opinion by a European Drug Regulator. Here’s What You Need to Know About It.
Two experts discuss the history of the ring, how it works, and when it may come to the United States.
Aug. 13, 2020: HCV testing rates among people newly diagnosed with HIV; HCV treatment referrals ammong coinfected people; HIV mortality rates despite free treatment access; mysterious, plummeting CD4 test results.